Important: Piciclib 125 is a prescription anticancer medicine. It should be used only under the supervision of a qualified oncologist or other healthcare professional. The information below is for educational purposes and should not replace professional medical advice.

What is Piciclib 125?

Piciclib 125 contains palbociclib 125 mg, an anticancer medicine belonging to a group called cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The product shown in the supplied image is marketed by Cipla Ltd and is supplied as capsules.

Palbociclib is used as part of combination treatment for certain patients with hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer. Depending on the clinical situation, it is used alongside appropriate endocrine therapy, such as an aromatase inhibitor or fulvestrant.

Cancer cells can multiply rapidly because signals controlling cell division become abnormal. Palbociclib works by blocking CDK4 and CDK6, proteins involved in progression through the cell cycle. By interfering with these signals, it can slow the multiplication of certain cancer cells.

Piciclib 125 is therefore not a general pain-relieving or symptom-relieving medicine. It is a specialized anticancer treatment selected by a doctor according to the patient’s cancer characteristics, previous treatment, overall health, and laboratory results.

Piciclib 125 Uses

Piciclib 125 is used in the management of certain forms of HR-positive, HER2-negative advanced or metastatic breast cancer, generally in combination with hormone-based anticancer treatment.

Its use may include:

• Treatment of selected HR-positive, HER2-negative advanced breast cancer.
• Treatment of selected HR-positive, HER2-negative metastatic breast cancer.
• Combination treatment with endocrine therapy when clinically appropriate.
• Disease management when a CDK4/6 inhibitor is considered suitable by the treating oncologist.

The exact treatment combination depends on the patient’s diagnosis and previous therapy. This medicine should only be taken under the supervision of a qualified healthcare professional.

Piciclib 125 Benefits

Piciclib 125 is intended to provide a targeted approach to controlling the growth of certain breast cancer cells.

Potential clinical benefits may include:

• Helping slow the progression of certain HR-positive, HER2-negative breast cancers.
• Blocking CDK4/6 activity involved in cancer-cell division.
• Supporting endocrine-based cancer treatment when prescribed in combination.
• Providing an established targeted-treatment option for eligible patients.

These benefits should not be interpreted as a guarantee of tumor shrinkage, remission, or cure. Individual responses to anticancer treatment vary, and treatment effectiveness is assessed by the oncology team.

How Does Piciclib 125 Work?

Palbociclib targets CDK4 and CDK6, enzymes that help regulate the cell cycle.

In many cancers, abnormal signaling can encourage cells to continue dividing. CDK4 and CDK6 help phosphorylate the retinoblastoma protein, allowing cells to progress from the G1 phase toward DNA synthesis.

Palbociclib inhibits CDK4/6 activity. This can produce cell-cycle arrest and reduce the ability of susceptible cancer cells to multiply. Because hormone receptor signaling can also contribute to breast cancer-cell growth, palbociclib is commonly combined with endocrine therapy in appropriate patients.

Piciclib 125 Dosage and Administration

The 125 mg strength shown on the product packaging is not a personalized dose recommendation. Palbociclib treatment schedules and any dose modifications must be determined by the prescribing oncologist.

Patients should:

• Take the medicine exactly as prescribed.
• Follow the treatment schedule provided by their oncology team.
• Swallow capsules whole rather than opening, crushing, or chewing them.
• Take the medicine with food when instructed for the capsule formulation.
• Never change, skip, or repeat doses without medical advice.
• If a dose is missed or vomiting occurs after taking a dose, follow the specific instructions provided by the treating healthcare professional rather than taking an extra dose.

The FDA prescribing information also emphasizes that capsules should be swallowed whole and that an additional dose should not be taken after vomiting or a missed dose.

Piciclib 125 Side Effects

Like all medicines, Piciclib 125 may cause side effects, although not everyone experiences them.

Common Side Effects

Reported adverse effects associated with palbociclib include:

• Neutropenia, or reduced neutrophil count
• Reduced white blood cell count
• Anemia
• Fatigue
• Infections
• Nausea
• Mouth inflammation or sores
• Diarrhea
• Hair loss
• Rash
• Reduced appetite
• Vomiting
• Low platelet count
• Fever or weakness

Blood-count abnormalities, particularly neutropenia, are an important safety concern with palbociclib and require appropriate monitoring.

Serious Side Effects

Prompt medical attention is important if a patient develops:

• Fever or symptoms suggesting an infection.
• Severe weakness or unusual bleeding/bruising.
• New or worsening breathing problems.
• Severe or persistent symptoms that concern the patient.

Palbociclib can cause significant suppression of bone-marrow blood-cell production. Rare but serious lung inflammation, including interstitial lung disease or non-infectious pneumonitis, has also been reported.

If side effects persist or become severe, contact your healthcare provider promptly.

Warnings and Precautions

Blood Counts and Infection

Because palbociclib can lower blood-cell counts, doctors generally monitor blood tests during treatment. Patients should promptly report fever, chills, signs of infection, unusual bruising, or other concerning symptoms.

Pregnancy

Palbociclib may cause fetal harm. Patients who are pregnant, planning pregnancy, or who could become pregnant should discuss the treatment with their healthcare professional before therapy. Appropriate contraception should be discussed with the treating team.

Breastfeeding

Breastfeeding is not recommended during palbociclib treatment because of the potential for serious adverse effects in a breastfed child. Patients should discuss feeding options with their healthcare professional.

Liver or Kidney Problems

Tell the doctor about existing liver or kidney problems. The patient’s medical condition may affect treatment decisions and monitoring requirements.

Lung Symptoms

New or worsening cough, breathing difficulty, or other unexplained respiratory symptoms should be reported promptly because lung inflammation has been reported with palbociclib.

Driving and Alcohol

Fatigue or other treatment-related symptoms may affect an individual’s ability to perform activities requiring concentration. Patients should discuss alcohol consumption and driving with their healthcare professional rather than assuming they are safe during treatment.

Drug Interactions

Palbociclib is metabolized mainly through the CYP3A pathway and can interact with medicines that strongly affect this enzyme system. Strong CYP3A inhibitors and strong CYP3A inducers can substantially alter palbociclib exposure.

Patients should tell their doctor or pharmacist about:

• Prescription medicines
• Over-the-counter medicines
• Vitamins
• Herbal products
• Supplements
• Medicines used for infections or other chronic conditions

Grapefruit and grapefruit products should be avoided during treatment, according to the FDA prescribing information.

This is not an exhaustive interaction list, so every medicine and supplement should be reviewed by the treating healthcare professional.

Storage Instructions

Follow the storage conditions printed on the product packaging or provided by the pharmacist.

General precautions include:

• Keep the medicine in its original packaging.
• Protect it from inappropriate heat, moisture, and direct sunlight.
• Keep it out of reach of children.
• Do not use capsules after their expiry date.
• Do not use damaged or compromised capsules.
• Do not transfer prescription medicines into unlabelled containers.

The precise storage requirements can vary by formulation and market, so the product label should take priority.

Piciclib 125 Price

The price of Piciclib 125 can vary according to pack size, pharmacy, location, taxes, and applicable pricing regulations. Because medicine prices can change, a current price should be confirmed through a licensed pharmacy or the product’s official market information rather than relying on an old online listing.

Piciclib 125 Manufacturer

The product shown is Piciclib 125, containing palbociclib 125 mg, and is identified as being marketed/manufactured by Cipla Ltd. Indian pharmacy listings also identify Cipla Ltd as the marketer of Piciclib 125.

Frequently Asked Questions

1. What is Piciclib 125 used for?

Piciclib 125 contains palbociclib, a CDK4/6 inhibitor used for certain patients with HR-positive, HER2-negative advanced or metastatic breast cancer. It is generally prescribed as part of combination treatment with endocrine therapy. The exact treatment plan depends on the patient’s cancer characteristics and medical history.

2. How does Piciclib 125 work?

Palbociclib blocks the CDK4 and CDK6 proteins involved in cell-cycle progression. Blocking these proteins can prevent susceptible cancer cells from progressing through the cell cycle and multiplying. It is therefore considered a targeted anticancer treatment rather than conventional symptom-relief medication.

3. Is Piciclib 125 safe?

Piciclib 125 can be an appropriate treatment for eligible patients when prescribed and monitored by an oncology team. However, it can cause significant side effects, particularly reductions in blood-cell counts. Medical monitoring is important throughout treatment.

4. Can Piciclib 125 be used long term?

Treatment duration varies between patients. An oncologist determines whether treatment should continue based on cancer response, side effects, laboratory findings, and overall clinical circumstances. Patients should not decide independently how long to continue treatment.

5. What happens if a dose is missed?

Patients should follow the missed-dose instructions supplied by their oncology team. The FDA labeling states that an additional dose should not be taken to compensate for a missed dose.

6. Can Piciclib 125 be stopped suddenly?

Patients should not stop or change prescribed anticancer treatment without discussing it with their oncologist. Treatment interruptions or dose changes may sometimes be medically necessary, but these decisions should be made by the treating healthcare professional.

7. Can Piciclib 125 be taken with food?

For the capsule formulation, the FDA prescribing information instructs patients to take palbociclib with food. The medicine should be taken according to the specific instructions supplied with the prescription.

8. What are the common Piciclib 125 side effects?

Common adverse effects can include reduced blood-cell counts, infections, fatigue, nausea, mouth sores, diarrhea, hair loss, rash, vomiting, decreased appetite, anemia, and low platelet counts. The severity and combination of side effects vary among patients.

9. Who should avoid or use Piciclib 125 with special caution?

Anyone considering palbociclib should first be evaluated by an oncology professional. Particular attention may be needed in people with blood-count abnormalities, liver problems, pregnancy, or significant medication interactions. The prescribing team should receive a complete medication and medical-history list.

10. How should Piciclib 125 be stored?

Keep Piciclib 125 in its original packaging and follow the storage instructions printed on the medicine pack. Protect it from unsuitable temperatures, moisture, and direct sunlight, and keep it away from children. Do not use the product after its expiry date.

Disclaimer

This product description is provided for general educational purposes only and is not medical advice. Piciclib 125 is a prescription anticancer medicine and should be used only under the supervision of a qualified healthcare professional. Do not self-medicate, alter the prescribed treatment schedule, or make treatment decisions based solely on information found online. Individual responses, risks, and treatment requirements vary. Always follow the prescription and instructions provided by the treating oncology team.